Biogen Inc

Biogen Inc has agreed to pay $22 million to resolve U.S. allegations that it illegally used two charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay them kickbacks to use its multiple sclerosis drugs.

Biogen said on Thursday it filed for regulatory approval in Japan for an Alzheimer's disease drug it developed with local partner Eisai Co.

Biogen Inc will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders, the two companies said on Friday.

Biogen Inc has entered into an agreement with Sage Therapeutics to jointly develop and sell a treatment for major depressive disorder, the two companies said on Friday.

Healthcare and chemicals group Merck KGaA <MRCG.DE> lifted its guidance for full year earnings after the scramble to ready treatments and vaccines against the coronavirus bolstered demand for its supplies for biotech labs.

Biogen Inc's <BIIB.O> shares slumped about 30% on Monday as the drugmaker's chances of getting a regulatory approval for its experiment Alzheimer's treatment suffered a blow after a panel of experts to the U.S. Food and Drug Administration voted against the medicine.

A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted that a potential Alzheimer’s treatment from Biogen Inc has not been proven to slow progression of the disease, a sharp rebuke to agency staff who earlier this week praised the drug.

A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted that one of two large studies on Biogen Inc's experimental Alzheimer's disease drug cannot be viewed alone without regard for the other failed trial.

A meeting of outside advisers to the U.S. Food and Drug Administration convened on Friday to discuss whether to recommend approval of Biogen Inc's experimental Alzheimer's disease drug aducanumab.

Biogen Inc has shown "exceptionally persuasive" evidence that its experimental Alzheimer's disease drug is effective, U.S. Food and Drug Administration staff said on Wednesday, elevating its chances of a swift approval and sending company shares soaring.

* U.S. FDA STAFF SAYS BIOGEN INC HAS PROVIDED SUBSTANTIAL EVIDENCE OF EFFECTIVENESS TO SUPPORT APPROVAL OF ALZHEIMER’S DRUG: DOCUMENTS Source: (https://bit.ly/3exlbFx) Further company coverage:

U.S. health experts this week will decide whether to recommend approval for Biogen Inc's <BIIB.O> Alzheimer's drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if it works.

The U.S. Food and Drug Administration, citing conflict of interest, has recused a member of an 11-person advisory committee set to review Biogen Inc's experimental Alzheimer's drug aducanumab on Friday.

Biogen Inc and Eisai Co Ltd said on Friday the European health regulator has accepted for review the marketing application for their closely watched experimental Alzheimer's treatment aducanumab.

Biogen Inc and partner Eisai Co Ltd said on Friday the European health regulator has accepted for review the marketing application for its closely-watched experimental Alzheimer's treatment aducanumab.

Biogen Inc <BIIB.O> said on Wednesday it was diverting part of its budget and resources for blockbuster multiple sclerosis drug Tecfidera towards a potential launch of its Alzheimer's disease drug, aducanumab.

* BIOGEN INC CEO SAYS UPCOMING FDA PANEL MEETING FOR ADUCANUMAB IS CO'S HIGHEST PRIORITY: CONF. CALL

U.S. drugmaker Biogen Inc and gene-editing startup Scribe Therapeutics Inc will jointly develop therapies for treating underlying genetic causes of amyotrophic lateral sclerosis (ALS), a fatal neurological disorder better known as Lou Gehrig's disease.

Note: This story has been corrected to name Merck KGaA, not Merck & Co, in the first paragraph.